非裔美国肾细胞癌患者癌症特异性与总生存结局的差异:来自国际肾癌标志物联盟(INMARC)的分析
非裔美国人I期和乳头状肾细胞癌比例更高,但多因素分析显示非裔美国人仍与更差的总生存(HR=1.24)和癌症特异性生存(HR=1.48)独立相关,III/IV期生存差异显著。
要点
- 非裔美国人I期占比73.8% vs 63.9%,乳头状肾细胞癌29.8% vs 8.5%,均P<.001。
- 多因素分析显示非裔美国人与更差总生存(HR=1.24,P=.027)和癌症特异性生存(HR=1.48,P=.025)相关。
- Kaplan-Meier分析显示非裔美国人III期和IV期总生存及癌症特异性生存均更差。
核心结论
- 尽管非裔美国人表现出更惰性的组织学和更低分期,但其总生存和癌症特异性生存更差,III/IV期差异显著,需进一步研究相关因素。
主要发现
- 非裔美国人I期占比73.8% vs 非非裔美国人63.9%(P<.001),乳头状肾细胞癌占比29.8% vs 8.5%(P<.001)。
- 多因素分析显示与总生存恶化相关的因素包括:年龄增加(HR=1.03,P<.001)、非裔美国人(HR=1.24,P=.027)、更高分期(HR=1.30-3.19,P<.001)、根治性肾切除术(HR=2.45,P<.001)、透明细胞型(HR=1.23,P<.001)、切缘阳性(HR=1.34,P=.004)和高分级(HR=1.58,P<.001)。
- 预测癌症特异性生存的因素包括:年龄增加(HR=1.02,P<.001)、非裔美国人(HR=1.48,P=.025)、根治性肾切除术(HR=2.98,P<.001)、高分级(HR=3.11,P<.001)和更高分期(HR=3.03-13.2,P<.001)。
- Kaplan-Meier分析显示非裔美国人5年总生存更差:I期80% vs 88%(P=.001)、III期26% vs 70%(P=.001)、IV期23% vs 44%(P=.009)。
- 非裔美国人5年癌症特异性生存更差:III期36% vs 81%(P<.001)、IV期30% vs 49%(P=.007)。
局限性
- 原文结论指出需要进一步研究与非裔美国人肾细胞癌生存差异相关的因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate association of African-American race and survival in Renal Cell Carcinoma (RCC). PATIENTS AND METHODS: We queried the International Marker Consortium for Renal Cancer database for patients who underwent partial or radical (RN) nephrectomy. The cohort was divided into African American (AA) and non-African American (NAA) patients. Primary outcome was all-cause mortality. Secondary outcome was cancer-specific mortality. Multivariable Analysis and Kaplan-Meier Analysis were used to elucidate predictive factors and survival outcomes. RESULTS: Three thousand eight hundred and ninety-three patients were analyzed (AA, n = 564/NAA, n = 3329). AA had greater Stage I (73.8% vs 63.9%, P <.001) and papillary RCC (29.8% vs 8.5%, P <.001). Multivariable Analysis revealed increasing age (HR = 1.03, P <.001), AA (HR = 1.24, P = .027), higher stage (HR = 1.30-3.19, P <.001), RN (HR = 2.45, P <.001), clear cell (HR = 1.23, P <.001), positive margin (HR = 1.34, P .004), and high-grade (HR = 1.58, P <.001) to be associated with worsened all-cause mortality. Increasing age (HR = 1.02, P <.001), AA (HR = 1.48, P = .025), RN (HR = 2.98, P <.001), high-grade (HR = 3.11, P <.001), and higher stage (HR = 3.03-13.2, P <.001) were predictive for cancer-specific mortality. Kaplan-Meier Analysis revealed worsened 5-year overall survival for AA in stage I (80% vs 88%, P = .001), stage III (26% vs 70%, P = .001), and stage IV (23% vs 44%, P = .009). Five-year cancer-specific survival was worse for AA in stage III (36% vs 81%, P <.001) and stage IV (30% vs 49%, P = .007). CONCLUSION: Despite presenting with more indolent histology and lower stage, African-Americans were at greater risk for diminished survival, faring worse in overall survival for all stages and cancer-specific survival in for stage III/IV RCC. Further investigation into factors associated with these disparities is warranted.
引用
- Meagher MF, Patil D, Saito K, et al. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology. 2022. PMID: 34995562. doi:10.1016/j.urology.2021.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。